DIRS.INFO The most relevant business & tech news

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Here are Monday's biggest analyst calls: Nvidia, Tesla, Apple, AbbVie, Chevron, Krispy Kreme, Roku and more
▼ + stars: | 2023-10-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are the biggest calls on Wall Street on Monday: JPMorgan upgrades Eastman Chemical to overweight from neutral JPMorgan said it sees an earnings rebound for Eastman Chemical. Bank of America reiterates Roku Bank of America said it's standing by its buy rating heading into earnings later this week. JPMorgan downgrades Olin to neutral from overweight JPMorgan downgraded the chemical company citing concerns about reduced product demand. " JPMorgan downgrades Valley National to neutral from overweight JPMorgan downgraded the regional bank mainly on valuation. Bank of America initiates Cooper Companies as buy Bank of America said the contact lens company is well positioned. "

Persons: Bernstein, Tesla, underperform Bernstein, Morgan Stanley, Apple, it's, Pinterest, Raymond James downgrades, Raymond James, TD Cowen, Decker, Baird downgrades Datadog, Baird, JPMorgan downgrades Newell, JPMorgan downgrades Olin, Olin, Harris, Hess, Truist, Piper Sandler, Piper, Oppenheimer, Goldman Sachs, Okta, Goldman, Wolfe Organizations: JPMorgan, Eastman Chemical, Barclays, Bank of America, Roku Bank of America, Apple, Citi, Raymond James downgrades Cisco, Cisco, Stanley Black, JPMorgan downgrades, JPMorgan downgrades Newell Brands, Newell Brands, UBS, East West Bancorp, Chevron, of America, Cooper Companies, Microsoft, MSFT, Deutsche Bank, Nvidia, Deutsche, Broadcom Locations: China, Okta

☆ Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
▼ + stars: | 2023-02-09 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Still, the outlook for biotech stocks could improve now , with innovation in new drugs and more merger and acquisition activity driving investor interest. Recently, Wall Street has been zoning in on developments in treatments for Alzheimer's diseases, drugs for weight loss and treatments using gene editing. CNBC Pro screened for biotech stocks that are part of the iShares Biotechnology ETF , searching for names with huge upside from current prices. In January, Piper Sandler initiated research coverage of Karuna with an overweight rating, saying it's "blazing a new trail in Schizophrenia" treatments. The stock was named another top 2023 pick by Piper Sandler, which said Legend has a "best-in-class" treatment for adults with relapsed multiple myeloma, a segment "with demand far outpacing supply."

☆ Analysts love these AI stocks with big upside potential to play the ChatGPT-driven artificial intelligence craze
▼ + stars: | 2023-02-07 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Each name in the list that follows has potential upside of about 35% or more, buy ratings from at least 60% of analysts and at least 10 analysts covering the stock. It has about 39% potential upside and buy ratings from almost 62% of the analysts covering it. Intellia Therapeutics , a company focused on gene-editing treatments, has upside potential of about 140% and buy ratings from 72% of its 27 analysts. Denali Therapeutics , which is focused on defeating neurodegenerative diseases, is close behind, with upside potential of 104% and buy ratings from almost 89% of its 18 analysts. Karuna Therapeutics , which specializes in schizophrenia treatments, holds the largest percentage of buy ratings, coming from 95% of its 20 analysts.

☆ This biotech stock is up 10% in the last month — and analysts expect it to rise a further 118%
▼ + stars: | 2023-01-19 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Wall Street is bullish on the California-headquartered company, which makes the enzymes for Pfizer's Covid-19 oral antiviral treatment ; all eight equity analysts covering the stock give it a buy rating. Their median price target points to a 118% potential upside over the 12 months, according to FactSet. "We believe that PRGN's R & D event will validate the key value propositions that underscore PRGN-2012," said Cantor Fitzgerald's analysts in a note to clients on Jan. 12. Other companies on the list include the London-listed stock of Oxford Nanopore Technologies and Genus , which analysts expect to rise by more than 40% over the next 12 months. Clinical diagnostics company Bio-Rad Lab and Sweden-headquartered IVF specialist Vitrolife are the other stocks expected to go up by analysts.

A decade ago, CAR T cell therapy changed the world of cancer treatment, offering a personalized approach to patients with blood cancers like leukemia. A novel approach to CAR T (chimeric antigen receptor T cell) therapy aims to cut down that turnaround time significantly. Instead of reprogramming each patient's cells, researchers are testing the safety of using universal, or "off the shelf," CAR T cells from other patients, preprogrammed to fight cancer. Scientists at University College London in the United Kingdom tested the safety of the experimental approach in six children — mostly toddlers — with advanced leukemia. One particular side effect associated with CAR T therapy is called a cytokine storm, and it can be deadly.

Search resuls for: "Cellular Therapies"

6 mentions found